E. M. Lindholm

miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.

A. Børresen-Dale, C. Caldas, E. M. Lindholm, 2019, MicroRNA.

Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal‐ and luminal‐like breast cancer xenografts

E. M. Lindholm, L. Akslen, G. Mælandsmo, 2012, Molecular oncology.

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer

A. Børresen-Dale, E. M. Lindholm, V. Kristensen, 2019, Molecular oncology.

Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations

G. Mills, E. M. Lindholm, G. Mælandsmo, 2013, Clinical Cancer Research.

Low‐molecular contrast agent dynamic contrast‐enhanced (DCE)‐MRI and diffusion‐weighted (DW)‐MRI in early assessment of bevacizumab treatment in breast cancer xenografts

Olav Engebraaten, Siver A Moestue, E. M. Lindholm, 2013, Journal of magnetic resonance imaging : JMRI.

Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts

T. Sørlie, A. Børresen-Dale, E. M. Lindholm, 2013, Molecular oncology.

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models

A. Børresen-Dale, E. M. Lindholm, B. Sitter, 2010, BMC Cancer.

In vivo MRI and histopathological assessment of tumor microenvironment in luminal‐like and basal‐like breast cancer xenografts

E. M. Lindholm, T. Bathen, I. Gribbestad, 2012, Journal of magnetic resonance imaging : JMRI.